

**SUPPLEMENTARY TABLES**

**Appendix 1: Predictors of ICU Admission, SIRS Development, and Local Complications**

		ICU Admission		SIRS Development		Local Complications	
		Univariate OR (95% CI)	Multivariate OR (95% CI)	Univariate OR (95% CI)	Multivariate OR (95% CI)	Univariate OR (95% CI)	Multivariate OR (95% CI)
Admission PASS > 140		4.7 (2.6, 8.5)*	4.9 (2.5, 9.4)**	3.0 (1.9, 4.6)*	2.9 (1.8, 4.5)**	3.1 (1.7, 5.7)*	3.0 (1.6, 5.7)**
Hematocrit > 44		2.4 (1.4, 4.2)*	2.4 (1.2, 4.6)**	2.1 (1.3, 3.2)*	1.7 (1.2, 3.3)**	1.0 (0.5, 1.9)	---
BUN>20		3.4 (1.8, 5.8)*	2.4 (1.2, 4.8)**	0.7 (0.4, 1.2)	---	0.9 (0.4, 2.0)	---
Comorbidities		2.3 (1.4, 3.9)*	2.3 (1.2, 4.4)**	0.7 (0.5, 1.2)	---	0.8 (0.4, 1.4)	---
Altered Mental Status		5.1 (1.8, 13.5)*	8.9 (2.7, 29.6)**	1.4 (0.5, 3.9)	---	1 (0.2, 4.5)	---
Age		1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)
Hispanic		0.8 (0.4, 1.6)	1.9 (0.5, 2.1)	1.6 (0.9, 3.0)	1.7 (0.9, 3.2)	0.8 (0.4, 1.6)	0.8 (0.4, 1.9)
Female		0.5 (0.3, 0.8)*	0.8 (0.4, 1.6)	0.9 (0.6, 1.4)	1.2 (0.7, 2.2)	1 (0.6, 1.8)	1.2 (0.6, 2.4)
Origin	Alcohol	Baseline 1.0	Baseline 1.0	Baseline 1.0	Baseline 1.0	Baseline 1.0	Baseline 1.0
	Gallstone	0.8 (0.4, 1.5)	1.4 (0.5, 3.0)	0.9 (0.6, 1.6)	0.9 (0.5, 1.7)	0.9 (0.4, 1.8)	0.8 (0.4, 1.9)
	Other	0.7 (0.4, 1.5)	0.8 (0.3, 2.0)	0.5 (0.3, 1.0)	0.6 (0.3, 1.0)	0.7 (0.3, 1.6)	0.7 (0.3, 1.7)

\*p<0.05 in univariate analysis, \*\*p<0.05 in multivariate analysis ---not included in multivariate model given insignificant in univariate model

**Appendix 2: PASS versus Glasgow for Additional Inpatient Outcomes**

	Admission Test	AUC	Cutoff	OR	95% CI	Sensitivity	Specificity	PPV	NPV
ICU Admission	PASS	0.74	140	4.7	2.6-8.5	0.73	0.64	0.26	0.93
ICU Admission	Glasgow	0.74	2	4.1	2.5-6.9	0.38	0.92	0.47	0.89
Local Complication	PASS	0.71	140	3.1	1.7-5.7	0.65	0.61	0.18	0.94
Local Complication	Glasgow	0.60	2	1.6	0.9-2.9	0.20	0.97	0.03	0.98
SIRS after Admission	PASS	0.66	140	3.0	1.9-4.6	0.64	0.63	0.37	0.83
SIRS after Admission	Glasgow	0.56	2	1.2	0.8-1.9	0.12	0.85	0.25	0.74

**Appendix 3: Predictors of Early ED, Late (>30 days) Readmission**

	Early (<30 days) ER Readmission		Late (>30 days) Readmission	
	Univariate OR (95% CI)	Multivariate OR (95% CI)	Univariate OR (95% CI)	Multivariate OR (95% CI)
Discharge PASS > 60	3.3 (1.4, 7.8)	3.2 (1.3, 7.7)	0.7(0.3, 1.7)	0.8(0.3, 1.9)
Age	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0(1.0, 1.0)	1.0(0.9, 1.0)
Hispanic	0.5 (0.2, 1.3)	0.5(0.2, 1.4)	1.0 (0.3, 2.6)	1.0(0.4, 3.0)
Female	1.2 (0.5, 2.9)	1.6(0.6, 4.4)	0.6(0.2, 1.3)	1.2(0.4, 3.4)

Etiology	Alcohol	Baseline 1.0	Baseline 1.0	Baseline 1.0	Baseline 1.0
	Gallstone	0.4 (0.1, 1.2)	0.3 (0.1, 1.1)	0.1 (0, 0.4)	0.1(0, 0.3)
	Other	1.4 (0.5, 3.7)	0.9 (0.3, 2.8)	0.2 (0.2, 1.2)	0.4(0.2, 1.0)

## REFERENCES

1. Vege SS, Atwal T, Bi Y, et al. Pentoxifylline Treatment in Severe Acute Pancreatitis: A Pilot, Double-Blind, Placebo-Controlled, Randomized Trial. *Gastroenterology* 2015;149:318-20 e3.
2. Isenmann R, Runzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. *Gastroenterology* 2004;126:997-1004.
3. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. *Gut* 2001;48:62-9.
4. Bakker OJ, van Brunschot S, van Santvoort HC, et al. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. *N Engl J Med* 2014;371:1983-93.
5. Buxbaum JL, Quezada M, Da B, et al. Early Aggressive Hydration Hastens Clinical Improvement in Mild Acute Pancreatitis. *Am J Gastroenterol* 2017;112:797-803.
6. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. *N Engl J Med* 2017;376:1551-1560.
7. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med* 2015;372:1104-13.

8. Wu BU, Batech M, Quezada M, et al. Dynamic Measurement of Disease Activity in Acute Pancreatitis: The Pancreatitis Activity Scoring System. *Am J Gastroenterol* 2017;112:1144-1152.
9. Mounzer R, Langmead CJ, Wu BU, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology* 2012;142:1476-82; quiz e15-6.
10. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2010;105:435-41; quiz 442.
11. Lee PJ, Bhatt A, Lopez R, et al. Thirty-Day Readmission Predicts 1-Year Mortality in Acute Pancreatitis. *Pancreas* 2016;45:561-4.
12. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med* 2009;360:1418-28.
13. Singh VK, Wu BU, Bollen TL, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. *Clin Gastroenterol Hepatol* 2009;7:1247-51.
14. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62:102-11.
15. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. *Crit Care Med* 1995;23:1638-52.
16. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386:1261-1268.
17. Lankisch PG, Weber-Dany B, Hebel K, et al. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol* 2009;7:702-5; quiz 607.
18. Brown A, James-Stevenson T, Dyson T, et al. The panc 3 score: a rapid and accurate test for predicting severity on presentation in acute pancreatitis. *J Clin Gastroenterol* 2007;41:855-8.
19. Afghani E, Pandol SJ, Shimosegawa T, et al. Acute Pancreatitis-Progress and Challenges: A Report on an International Symposium. *Pancreas* 2015;44:1195-210.
20. Lum HD, Studenski SA, Degenholtz HB, et al. Early hospital readmission is a predictor of one-year mortality in community-dwelling older Medicare beneficiaries. *J Gen Intern Med* 2012;27:1467-74.

21. Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. *JAMA* 2013;309:587-93.
22. Zuckerman RB, Sheingold SH, Orav EJ, et al. Readmissions, Observation, and the Hospital Readmissions Reduction Program. *N Engl J Med* 2016;374:1543-51.
23. Vippera K, Papachristou GI, Easler J, et al. Risk of and factors associated with readmission after a sentinel attack of acute pancreatitis. *Clin Gastroenterol Hepatol* 2014;12:1911-9.
24. Whitlock TL, Repas K, Tignor A, et al. Early readmission in acute pancreatitis: incidence and risk factors. *Am J Gastroenterol* 2010;105:2492-7.
25. Yadav D, O'Connell M, Papachristou GI. Natural history following the first attack of acute pancreatitis. *Am J Gastroenterol* 2012;107:1096-103.
26. Whitlock TL, Tignor A, Webster EM, et al. A scoring system to predict readmission of patients with acute pancreatitis to the hospital within thirty days of discharge. *Clin Gastroenterol Hepatol* 2011;9:175-80; quiz e18.
27. Wu BU, Bakker OJ, Papachristou GI, et al. Blood urea nitrogen in the early assessment of acute pancreatitis: an international validation study. *Arch Intern Med* 2011;171:669-76.
28. Muddana V, Whitcomb DC, Khalid A, et al. Elevated serum creatinine as a marker of pancreatic necrosis in acute pancreatitis. *Am J Gastroenterol* 2009;104:164-70.
29. Brown LA, Sofer T, Stilp AM, et al. Admixture Mapping Identifies an Amerindian Ancestry Locus Associated with Albuminuria in Hispanics in the United States. *J Am Soc Nephrol* 2017;28:2211-2220.